Comparing Annovis Bio (NYSE:ANVS) & RenovoRx (NASDAQ:RNXT)

Annovis Bio (NYSE:ANVS) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Annovis Bio and RenovoRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	0	2	3	0	2.60
RenovoRx	0	0	2	0	3.00

Annovis Bio presently has a consensus target price of $17.33, indicating a potential upside of 680.78%. RenovoRx has a consensus target price of $7.50, indicating a potential upside of 490.55%. Given Annovis Bio’s higher probable upside, research analysts plainly believe Annovis Bio is more favorable than RenovoRx.

Volatility and Risk

Annovis Bio has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.

Institutional and Insider Ownership

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by insiders. Comparatively, 9.1% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Annovis Bio and RenovoRx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$24.59 million	($2.04)	-1.09
RenovoRx	$662,000.00	70.30	-$8.81 million	($0.38)	-3.34

RenovoRx has higher revenue and earnings than Annovis Bio. RenovoRx is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Annovis Bio and RenovoRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-206.01%	-158.26%
RenovoRx	N/A	-120.68%	-89.23%

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

About RenovoRx

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.